Skip to content
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
Archyde

Archyde

  • News
  • World
  • Economy
  • Technology
  • Health
  • Entertainment
  • Sport

clinical studies

Satralizumab Sustains Proptosis Improvement in 85% of Responders With Thyroid Eye Disease at 48 Weeks

Satralizumab Sustains Proptosis Improvement in 85% of Responders With Thyroid Eye Disease at 48 Weeks

November 20, 2026 by Health Desk

Satralizumab (Enspryng) maintained reductions in eye bulging for roughly 85% of responders with thyroid eye disease through 48 weeks, according to pooled phase 3 data presented this week at the … Read More

Categories Health Tags clinical research, clinical studies, Clinical trials, eye, hyperthyroidism, Thyroid

Recent Posts

  • Trump Pardons Pete Rose Posthumously, Blasts MLB Hall of Fame Exclusion
  • Westminster and Kensington & Chelsea Bike Hangar Fees to Exceed Car Permit Costs in 2027
  • First-Ever Black Friday Discounts Hit M6 and PROLED XDR MacBook Pros: Up to $250 Off
  • SAME Director Alberto Crescenti Honored in Argentina’s Congress for Public Health Leadership
  • Trump Presses Europe to Engage Putin Directly After Shenzhen Summit
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
© 2026 Archyde — All Rights Reserved. Contact | Privacy Policy